UCBJY:OTCMKTS
UCB
112,60Â USD
arrow_upward
+1,64%(+1,82) 1G
14 ott, 16:00:00 GMT-4 · USD
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per UCBJY in corso…
Apertura
111,75Â USD
Massimo
112,93Â USD
Minimo
111,75Â USD
Cap. mercato
38,06Â Mld
Vol. medio
49,66K
Volume
93,92K
Max 52 sett.
168,76Â USD
Min 52 sett.
110,55Â USD
Beta
0,57
Azioni in circolazione
389,01Â Mln
N. di dipendenti
9K
Apertura
111,75Â USD
Massimo
112,93Â USD
Minimo
111,75Â USD
Cap. mercato
38,06Â Mld
Vol. medio
49,66K
Volume
93,92K
Max 52 sett.
168,76Â USD
Min 52 sett.
110,55Â USD
Beta
0,57
Azioni in circolazione
389,01Â Mln
N. di dipendenti
9K
Articoli giornalistici
Da fonti web e partner giornalistici
ad-hoc-news.de
·
21 ore fa
UCB dedicates Georgia site. UCB stock sits 30.78 percent below its high
ad-hoc-news.de
·
1 giorno fa
UCB launches Wear It Out program: UCB stock pre-market at EUR 198.60
ad-hoc-news.de
·
1 giorno fa
UCB presented Bimzelx data. UCB stock loses 1.06 percent.??
ad-hoc-news.de
·
2 giorni fa
UCB dedicated Georgia site. UCB stock sits below EUR 206.70
Profilo
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Informazioni su UCB